AilsynBio and Dong-E-E-Jiao Partner to Boost Traditional Medicine with Artificial Intelligence

AilsynBio and Dong-E-E-Jiao Co., Ltd. officially signed a strategic cooperation agreement at the Hong Kong Science Park on April 12, 2026. This partnership focuses on utilizing artificial intelligence to modernize Traditional Chinese Medicine and bridge the gap between empirical wisdom and modern clinical standards. The ceremony included prominent leaders from the China Resources Pharmaceutical Group and the University of Hong Kong to witness the milestone.

Advancing Evidence-Based Remedies

The alliance will leverage AilsynBio’s AI-native biotechnology platform to accelerate research and development processes for traditional remedies. By using physics-based modeling and deep medicinal chemistry, the team aims to identify the exact molecular mechanisms of action within herbal formulas. This scientific approach is intended to provide the rigorous evidence required for global regulatory acceptance and international market confidence.

A Focus on Women’s Health

A central component of the research targets Premature Ovarian Insufficiency using the flagship Compound E-Jiao Syrup from Dong-E-E-Jiao. Investigators plan to use AI-powered analysis to map out the synergistic effects of the syrup's multiple active compounds. This specialized research aims to solve complex reproductive health challenges that often frustrate conventional medical approaches alone.

Strategic Cross-Border Fusion

"This collaboration represents a deep integration of industry, academia, and research between Mainland China and Hong Kong," noted Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical. The project aligns with broader government efforts to build AI-driven models that assess clinical efficacy in ancient therapies. Success in this venture could significantly accelerate the commercialization of Hong Kong academic research while positioning TCM for global expansion. The partnership is viewed as a strategic layout for future healthcare innovation by injecting technological vitality into traditional sectors. By combining cutting-edge biotechnology with established empirical formulas, the collaboration seeks to unlock biological mechanisms that were previously untraceable. This initiative marks a new chapter for the health industry, promising modernized therapies for patients worldwide.